Perinatal PCP treatment alters the developmental expression of prefrontal and hippocampal muscarinic receptors

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 1, 2009, Pages 37-40

  du Bois, Teresa Marie ^a,b   Newell, Kelly Anne ^a,b   Han, Mei ^a,b   Deng, Chao ^a,b   Huang, Xu Feng ^a,b  

^a SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Brain development; Muscarinic receptor; NMDA receptor; Phencyclidine; Schizophrenia

Indexed keywords

MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PARVALBUMIN; PHENCYCLIDINE; PIRENZEPINE; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN DEVELOPMENT; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG RECEPTOR BINDING; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; HIPPOCAMPUS; HISTOPATHOLOGY; INHIBITORY POSTSYNAPTIC POTENTIAL; INTERNEURON; MALE; NEUROTRANSMISSION; NEWBORN; NONHUMAN; PERINATAL PERIOD; PREFRONTAL CORTEX; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA;

AGING; ANIMALS; ANIMALS, NEWBORN; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HIPPOCAMPUS; MUSCARINIC ANTAGONISTS; PHENCYCLIDINE; PIRENZEPINE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M4;

EID: 58149333627     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.10.001     Document Type: Article

References (41)

1. Andersen J.D., and Pouzet B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of d-serine. Neuropsychopharmacol 29 (2004) 1080-1090
2. Brooks W.J., Weeks A.C., Leboutillier J.C., and Petit T.L. Altered NMDA sensitivity and learning following chronic developmental NMDA antagonism. Physiol Behav 62 (1997) 955-962
3. Bymaster F.P., Felder C., Ahmed S., and McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Target CNS Neurol Disord 1 (2002) 163-181
4. Crook J.M., Tomaskovic-Crook E., Copolov D.L., and Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48 (2000) 381-388
5. Crook J.M., Tomaskovic-Crook E., Copolov D.L., and Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 158 (2001) 918-925
6. Dean B. M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia. Neuropsychopharmacol 29 (2004) 1583-1584
7. Dean B., Crook J.M., Opeskin K., Hill C., Keks N., and Copolov D.L. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1 (1996) 54-58
8. Deng C., and Huang X.-F. Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J Neurosci Res 81 (2005) 883-890
9. du Bois T.M., and Huang X.-F. Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia. Brain Res Rev 53 (2007) 260-270
10. du Bois T.M., Bell W., Deng C., and Huang X.-F. A high n-6 polyunsaturated fatty acid diet reduces muscarinic M2/M4 receptor binding in the rat brain. J Chem Neuroanat 29 (2005) 282-288
11. du Bois T.M., Huang X.-F., and Deng C. Perinatal administration of PCP alters adult behaviour in female Sprague-Dawley rats. Behav Brain Res 188 (2008) 416-419
12. Facchinetti F., Ciani E., Dall'Olio R., Virgili M., Contestabile A., and Fonnum F. Structural, neurochemical and behavioural consequences of neonatal blockade of NMDA receptor through chronic treatment with CGP 39551 or MK-801. Dev Brain Res 74 (1993) 219-224
13. Haj-Dahmane S., and Andrade R. Muscarinic activation of a voltage-dependent cation nonselective current in rat association cortex. J Neurosci 16 (1996) 3848-3861
14. 3H]acetylcholine release by striatal glutamate and dopamine receptors. Brain Res 844 (1999) 106-117
15. Harris L.W., Sharp T., Gartlon J., Jones D.N., and Harrison P.J. Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. Eur J Neurosci 18 (2003) 1706-1710
16. Hyde T.M., and Crook J.M. Cholinergic systems and schizophrenia: primary pathology or epiphenomena?. J Chem Neuroanat 22 (2001) 53-63
17. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. [See comment]. Am J Psychiatry 148 (1991) 1301-1308
18. Jentsch J.D., Dazzi L., Chhatwal J.P., Verrico C.D., and Roth R.H. Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats. Neurosci Lett 258 (1998) 175-178
19. Latysheva N.V., and Rayevsky K.S. Chronic neonatal N-methyl-d-aspartate receptor blockade induces learning deficits and transient hypoactivity in young rats. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 787-794
20. Li Z., Bonhaus D.W., Huang M., Prus A.J., Dai J., and Meltzer H.Y. AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus. Eur J Pharmacol 572 (2007) 129-137
21. Mancama D., Arranz M.J., Landau S., and Kerwin R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet 119B (2003) 2-6
22. Markram H., and Segal M. Long-lasting facilitation of excitatory postsynaptic potentials in the rat hippocampus by acetylcholine. J Physiol 427 (1990) 381-393
23. Minzenberg M.J., Poole J.H., Benton C., and Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 161 (2004) 116-124
24. Moreira K.M., Ferreira T.L., Fornari R.V., Figueredo L.Z.P., and Oliveira M.G.M. Interaction between M1-muscarinic and glutamatergic NMDA receptors on an inhibitory avoidance task. Brain Res Bull 67 (2005) 504-508
25. Mouri A., Noda Y., Enomoto T., and Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int 51 (2007) 173-184
26. Newell K.A., Zavitsanou K., Jew S.K., and Huang X.-F. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 225-233
27. Patel A.J., del Vecchio M., and Atkinson D.J. Effect of undernutrition on the regional development of transmitter enzymes: glutamate decarboxylase and choline acetyltransferase. Dev Neurosci 1 (1978) 41-53
28. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1986), Academic Press Inc., London
29. Porter A.C., Bymaster F.P., DeLapp N.W., Yamada M., Wess J., Hamilton S.E., et al. M1 muscarinic receptor signaling in mouse hippocampus and cortex. Brain Res 944 (2002) 82-89
30. Shekhar A., Potter W.Z., Lightfoot J., Lienemann J., Dube S., Mallinckrodt C., et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165 (2008) 1033-1039
31. Shelnutt S.R., Gunnell M., and Owens S.M. Sexual dimorphism in phencyclidine in vitro metabolism and pharmacokinetics in rats. J Pharmacol Exp Ther 290 (1999) 1292-1298
32. Sircar R. Postnatal phencyclidine-induced deficit in adult water maze performance is associated with N-methyl-d-aspartate receptor upregulation. Int J Dev Neurosci 21 (2003) 159-167
33. Stefani M.R., and Moghaddam B. Transient N-methyl-d-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol Psychiatry 57 (2005) 433-436
34. Sur C., Mallorga P.J., Wittmann M., Jacobson M.A., Pascarella D., Williams J.B., et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc Natl Acad Sci USA 100 (2003) 13674-13679
35. Tice M.A.B., Hashemi T., Taylor L.A., and McQuade R.D. Distribution of muscarinic receptor subtypes in rat brain from postnatal to old age. Dev Brain Res 92 (1996) 70-76
36. Vincent J.P., Cavey D., Kamenka J.M., Geneste P., and Lazdunski M. Interaction of phencyclidines with the muscarinic and opiate receptors in the central nervous system. Brain Res 152 (1978) 176-182
37. Wang C., McInnis J., Ross-Sanchez M., Shinnick-Gallagher P., Wiley J.L., and Johnson K.M. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107 (2001) 535-550
38. Wang C., McInnis J., West J.B., Bao J., Anastasio N., Guidry J.A., et al. Blockade of phencyclidine-induced cortical apoptosis and deficits in prepulse inhibition by M40403, a superoxide dismutase mimetic. J Pharmacol Exp Ther 304 (2003) 266-271
39. Wiley J.L., Buhler K.G., Lavecchia K.L., and Johnson K.M. Pharmacological challenge reveals long-term effects of perinatal phencyclidine on delayed spatial alternation in rats. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 867-873
40. Zavitsanou K., Katsifis A., Mattner F., and Huang X.-F. Investigation of M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacol 29 (2004) 619
41. Zmarowski A., Sarter M., and Bruno J.P. NMDA and dopamine interactions in the nucleus accumbens modulate cortical acetylcholine re lease. Eur J Neurosci 22 (2005) 1731-1740